Article
Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review.
Targeted oncology - 1 Jun 2020
Seghers An-Katrien, Cuyle Pieter-Jan, Van Cutsem Eric
Abstract excerpt
Current standard-of-care treatment for advanced pancreatic ductal adenocarcinoma is mainly based on conventional cytotoxic chemotherapy. Until recently, no randomized clinical trials had shown any clinically meaningful outcome benefit from targeted therapy in this indication. This is in contrast to many other tumor types. The majority of pancreatic tumors are driven by KRAS mutations, which are generally not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.